A 971-person randomized Phase II trial has pushed GSK’s experimental seasonal influenza vaccine into a Phase III efficacy study scheduled to begin this month. The company reported stronger antibody responses than licensed standard-dose shots in adults 18 to 64 and high-dose shots in adults 65 and older, according to its trial update.

The announcement matters because seasonal flu vaccines often provide only moderate and uneven protection. Yet the result is not proof that GSK’s candidate prevents more illness. The disclosed study measured immunogenicity—the immune system’s response—and safety, not laboratory-confirmed influenza. The planned Phase III trial must determine whether the stronger laboratory signals become fewer infections and complications in the real world.

What the Phase II Result Shows

GSK said the observer-blind Flu-028 study compared several mRNA formulations and dose levels with licensed, age-appropriate vaccines. The selected candidate, called FLUm3HA.b-3NA, encodes optimized influenza B hemagglutinin and neuraminidase targets alongside influenza A components. Immune responses were assessed against A and B strains, with safety and reactogenicity followed through 181 days after vaccination.

The company reported higher immune responses against every tested strain in both age groups and described the tolerability profile as acceptable. It did not, however, publish the response magnitudes, confidence intervals, adverse-event tables or prespecified statistical thresholds in its public release. Full results were presented at the OPTIONS XIII influenza conference, while the underlying data have not yet appeared in a peer-reviewed journal.

The public trial registry shows why the study was built as a selection exercise rather than a final efficacy test. Investigators evaluated multiple formulations and dose levels, stratified participants by age and compared immune responses after vaccination. That structure can identify a candidate for advancement, but the sample is far too small to estimate protection reliably across an influenza season.

That evidence boundary is important. Antibody measures can help researchers select a dose and decide whether a candidate is promising enough for a larger trial, but they do not capture every part of immune protection. A vaccine can outperform a comparator on a laboratory endpoint without necessarily delivering the same advantage against symptomatic disease, hospitalization or transmission.

A Second Influenza Target

Most licensed flu vaccines are designed principally around hemagglutinin, or HA, the surface protein that helps the virus attach to and enter cells. GSK’s formulation also deliberately encodes neuraminidase, or NA, which helps newly formed viral particles escape infected cells and spread. Both proteins change over time, requiring seasonal vaccine updates as circulating strains evolve.

The scientific case for adding a controlled NA target is plausible but unfinished. A widely cited review notes that conventional inactivated vaccines may contain neuraminidase, yet its amount and quality are generally variable and not standardized. Antibodies against NA have been associated with reduced disease and viral shedding, but researchers still lack fully harmonized assays and validated correlates of protection.

Encoding both targets gives developers more control over which antigens the body sees and could broaden protection if an HA match is imperfect. It could also help reduce severity rather than merely block infection. Those are testable hypotheses, not established benefits of this candidate. Phase III design, strain circulation and case accumulation will determine whether the additional target produces a clinically meaningful difference.

The Benchmark Has Already Moved

GSK will enter late-stage testing after the first U.S. approval of an mRNA seasonal flu vaccine. On August 5, the Food and Drug Administration licensed Moderna’s MFLUSIVA for adults 50 and older, according to the agency’s product page. Moderna’s vaccine encodes HA antigens; GSK is trying to distinguish its program by adding standardized NA expression.

The Moderna decision also illustrates why immune-response headlines require context. FDA granted traditional approval for ages 50 through 64 based on a clinical efficacy trial, but used accelerated approval for people 65 and older based on comparative antibody responses. The agency’s 123-page clinical review requires a postmarketing study to verify benefit in the older group and describes remaining uncertainty for the B/Victoria strain.

In Moderna’s 40,805-person efficacy study, the vaccine produced 26.6% relative efficacy over a standard-dose comparator against protocol-defined, PCR-confirmed influenza-like illness. That number does not mean 26.6% of all recipients avoided flu; it describes the relative reduction in cases between randomized groups. The precedent gives GSK a demanding and more modern comparator landscape, not an automatic regulatory route.

Why Better Protection Is Needed

Influenza remains a large and variable burden even when vaccination programs are functioning. The WHO) estimates roughly one billion infections, three million to five million severe cases and 290,000 to 650,000 respiratory deaths worldwide each year. Older adults, pregnant people and patients with chronic disease face disproportionate risks from severe illness.

Season-to-season performance changes with the match between vaccine strains and circulating viruses, the dominant subtype, age and underlying health. In U.S. observational networks, the Centers for Disease Control and Prevention estimated overall vaccine effectiveness at 36% for 2025–2026, compared with 56% the previous season, its historical table shows. Both estimates remain preliminary.

Moderate effectiveness does not make existing vaccines unhelpful. Even imperfect vaccination can avert outpatient visits, hospitalizations and deaths across a large population. The more precise question for GSK is whether its dual-target mRNA candidate improves protection enough to justify its safety profile, price, manufacturing demands and place among standard-dose, high-dose, adjuvanted and recombinant alternatives.

Older adults will be especially important because immune responses often weaken with age and U.S. guidance already favors enhanced vaccines for them. The CDC recommends high-dose inactivated, recombinant or adjuvanted vaccines for people 65 and older when available. A new candidate must therefore beat an elevated standard, not simply outperform an ordinary shot selected for younger adults.

Product performance is only one part of population impact. CDC coverage data indicate that 46.5% of U.S. adults reported receiving a flu vaccine by February 22 in the 2025–2026 season. A more effective option cannot prevent disease in people who do not receive it, so recommendations, supply, cost, clinician confidence and public acceptance will shape any eventual benefit.

The Phase III Questions

The planned efficacy trial should clarify the outcome that patients care about most: whether vaccination reduces confirmed influenza disease. Its credibility will depend on a prespecified case definition, adequate representation across ages and health conditions, comparison with the right licensed vaccines, transparent safety monitoring and enough circulation of each targeted strain to produce stable estimates.

Influenza efficacy trials also face a moving biological target. Researchers select vaccine strains months before a season, while the viruses continue to evolve and the mix of A and B infections varies by place and time. A low-activity season can leave too few cases for precise estimates; a mismatch can test whether broader antigen design actually adds resilience rather than merely producing higher antibody levels.

Safety evidence must also expand well beyond 971 participants. Common short-term reactions can be characterized in Phase II, but uncommon events require tens of thousands of recipients or post-authorization surveillance. Regulators will examine serious adverse events, withdrawals and reactions by age while weighing any incremental protection against potentially greater reactogenicity from an mRNA product.

GSK said the candidate received FDA Fast Track designation in July, which can increase communication with the agency and allow portions of an application to be reviewed as they are completed. It does not lower the legal standard for demonstrating safety and effectiveness, guarantee approval or substitute for a positive efficacy result.

A Promising Signal, Not a Verdict

The competitive backdrop is unusually useful for public health. Moderna’s approval establishes that mRNA can produce a licensed seasonal flu vaccine, while GSK’s program tests whether deliberately combining HA and NA can improve on that first generation. Other platforms continue to provide alternatives, making comparative effectiveness, access and uptake as consequential as technological novelty.

For now, the measured conclusion is narrow: GSK has enough Phase II immune-response and safety evidence to justify a much larger test. The Phase III trial, not the company’s conference presentation, will show whether the candidate prevents more influenza. Until case data arrive, “dual target” describes a rational design choice—not a demonstrated clinical advantage.